Karin Senn joins Swizzard as Medical Director
Updated: Oct 11, 2022
Swizzard Pharma AG, a solution provider to maximize the value of medical breakthroughs in Switzerland, welcomes Karin Senn as Medical Director as of 1 August 2022.
Karin holds a PhD in Biology from ETH Zurich and worked for several years in postdoctoral research, first at the Department of Experimental Immunology, University Hospital Zurich, and then at the Department for Gene Therapy and Molecular Medicine, Mount Sinai School of Medicine in New York.
In 2004, Karin moved into her first industry role and has since occupied various commercial and medical positions for companies such as Abbott, Daiichi Sankyo and Mitsubishi Tanabe Pharma. Experienced in several therapeutic areas, her scientific focus spans indications in infectious disease, cardiology and neurology. Most recently, Karin has been working as Medical Science Liaison Manager for AstraZeneca, contributing her medical expertise for the launch of a Critical Care antidote and building advocacy through scientific exchange with key stakeholders.
Her proven track record in the medical field and links to public and private stakeholders in Switzerland put her in an excellent position to help Swizzard’s clients achieve launch readiness from the medical perspective. Besides driving medical engagement initiatives with key opinion leaders, Karin will support Swizzard’s customers with the medical aspects of their go-to-market strategies.
“As a scientist first and foremost, I’m looking forward to bringing my expertise to bear in a broad range of indications and applications for Swizzard’s customers,” says Karin Senn.
“Karin has exceptional credentials and connections in the Swiss medical landscape,” says Michael Zürcher, CEO of Swizzard. “With her vast knowledge and experience, she will accelerate Swizzard’s efforts to bring medical breakthroughs to the Swiss market. We’re delighted to have her on board.”